ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
ACTUATE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.60−0.01 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $14.30M
- P/E (TTM)
- –
- Dividend yield
- –
Actuate Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Market Cap | $14.38M | $166.30M |
| Enterprise Value | $9.96M | $88.19M |
| PB Ratio | 14.54 | 2.03 |
| P/TBV Ratio | 14.54 | 2.29 |
Income (trailing twelve months)
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$20.77M | -$21.40M |
| Net Income | -$20.45M | -$22.46M |
| EBITDA | -$20.77M | -$16.91M |
| EPS (Diluted) | -$0.88 | -$0.83 |
Returns
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -336.2% | -40.9% |
| Return on Capital Employed (ROCE) | -1490.0% | -38.1% |
Balance sheet
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.43M | $61.43M |
| Net Cash (Debt) | $4.43M | $15.35M |
| Net Cash Per Share | $0.18 | $0.66 |
| Equity (Book Value) | $989.15K | $49.09M |
| Book Value Per Share | $0.04 | $1.37 |
| Tangible Book Value | $989.15K | $23.52M |
| Working Capital | $942.75K | $76.81M |
Financial position
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.25 | 3.34 |
| Quick Ratio | 1.16 | 2.44 |
| Interest Coverage | -1025.85 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$19.84M | -$12.35M |
Efficiency
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.70M | -$703.34K |
| Employee Count | 12 | 74 |
Dividends and yields
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -142.2% | -23.3% |
| Buyback Yield | -35.3% | -0.59% |
| Shareholder Yield | -35.3% | 0.00% |
Shares
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 24,014,200 | 58,127,000 |
| Shares Change (QoQ) | 1.27% | 0.54% |
| Float | 8,014,530 | 49,136,700 |
| Shares Held by Insiders | 66.6% | 11.6% |
| Shares Held by Institutions | 56.3% | 59.4% |
Scores
| Measure | Actuate Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -55.37 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Actuate Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.